
Transforming Drug Discovery and Disease Research—One Cell at a Time
About this episode
The ARC Virtual Cell Atlas uses high-throughput single-cell genomics, artificial intelligence, and open science to understand the complexities of cellular behavior. Developed through a partnership between the ARC Institute, 10x Genomics, and Ultima Genomics, the public domain resource integrates data from hundreds of millions of cells. By curating and harmonizing vast amounts of single-cell measurements, the Atlas paves the way for virtual cell simulations that can predict how cells respond to genetic or chemical changes. These models hold the promise for transforming drug discovery by accelerating target identification, optimizing candidate compounds, and reducing the cost of drug development. We spoke to Arc Institute’s Core Investigator Hani Goodarzi, Ultima Genomics CEO Gilad Almogy, and 10X Genomics CEO Serge Saxonov, about how the Atlas will serve academic and industry researchers developing therapies, how it will help unravel disease mechanisms at a cellular level, and provide broad access to advanced cellular analytics.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Bio Report

Resetting Severe Allergies at Their Cellular Source
The Bio Report

Innovating ADCs with Dual Targeting and Smarter Delivery
The Bio Report

Targeting the Brain’s Immune System in Alzheimer’s Disease
The Bio Report

How Gilead Is Building Durable Oncology and Immunology Franchises
The Bio Report